-+ 0.00%
-+ 0.00%
-+ 0.00%

RHYTHM PHARMACEUTICALS ANNOUNCES FDA EXTENSION OF REVIEW PERIOD FOR IMCIVREE® (SETMELANOTIDE) FOR PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY

Reuters·11/07/2025 12:30:00

Please log in to view news